Tags

Type your tag names separated by a space and hit enter

Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
Arq Bras Cardiol. 2000 Feb; 74(2):103-17.AB

Abstract

OBJECTIVE

To compare the regression of left ventricular hypertrophy in patients with moderate hypertension treated with enalapril, losartan or a combination of the two drugs at lower doses.

METHODS

Patients of both sexes with moderate hypertension confirmed by ambulatory monitoring of arterial blood pressure and with left ventricular hypertrophy on echocardiogram were assigned to three groups: enalapril (35 mg/day, n=15), losartan (175 mg/day, n=15) and enalapril losartan (15 mg+100 mg/day, n=16). The patients received the drugs for 10 months.

RESULTS

The three therapeutic regimens were equally effective in reducing blood pressure and left ventricular mass index (LVMI, g/m2): 141+/-3.9 to 123+/-3.6 in the enalapril group (p<0.05), from 147+/-3.8 to 133+/-2.8 in the losartan group (p<0.05), and from 146+/-3.0 to 116+/-4.0 in the enalapril+losartan group (p<0.05). However, the percent reduction of LVMI was significantly greater (p<0.01) in the enalapril+losartan group (20.5+/-5.0%) than in enalapril (12.4+/-3.2%) and the losartan (9.1+/-2.1%) groups. Normalization of LVMI was obtained in 10 out of the 16 patients who received enalapril+ losartan, in 6 out of the 15 patients who received only enalapril and in 4 out of the 15 patients treated with losartan.

CONCLUSION

The combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist (AT1 receptor antagonist) in patients produced an additional effect on the reduction of left ventricular hypertrophy. This finding may depend on a more complete inhibition of the cardiac renin-angiotensin.

Authors+Show Affiliations

Universidade Federal do Espríto Santo, Vitória, BrasilNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng por

PubMed ID

10904284

Citation

Avanza, A C., et al. "Reduction in Left Ventricular Hypertrophy in Hypertensive Patients Treated With Enalapril, Losartan or the Combination of Enalapril and Losartan." Arquivos Brasileiros De Cardiologia, vol. 74, no. 2, 2000, pp. 103-17.
Avanza AC, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol. 2000;74(2):103-17.
Avanza, A. C., El Aouar, L. M., & Mill, J. G. (2000). Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arquivos Brasileiros De Cardiologia, 74(2), 103-17.
Avanza AC, El Aouar LM, Mill JG. Reduction in Left Ventricular Hypertrophy in Hypertensive Patients Treated With Enalapril, Losartan or the Combination of Enalapril and Losartan. Arq Bras Cardiol. 2000;74(2):103-17. PubMed PMID: 10904284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. AU - Avanza,A C,Jr AU - El Aouar,L M, AU - Mill,J G, PY - 2000/7/25/pubmed PY - 2000/8/19/medline PY - 2000/7/25/entrez SP - 103 EP - 17 JF - Arquivos brasileiros de cardiologia JO - Arq Bras Cardiol VL - 74 IS - 2 N2 - OBJECTIVE: To compare the regression of left ventricular hypertrophy in patients with moderate hypertension treated with enalapril, losartan or a combination of the two drugs at lower doses. METHODS: Patients of both sexes with moderate hypertension confirmed by ambulatory monitoring of arterial blood pressure and with left ventricular hypertrophy on echocardiogram were assigned to three groups: enalapril (35 mg/day, n=15), losartan (175 mg/day, n=15) and enalapril losartan (15 mg+100 mg/day, n=16). The patients received the drugs for 10 months. RESULTS: The three therapeutic regimens were equally effective in reducing blood pressure and left ventricular mass index (LVMI, g/m2): 141+/-3.9 to 123+/-3.6 in the enalapril group (p<0.05), from 147+/-3.8 to 133+/-2.8 in the losartan group (p<0.05), and from 146+/-3.0 to 116+/-4.0 in the enalapril+losartan group (p<0.05). However, the percent reduction of LVMI was significantly greater (p<0.01) in the enalapril+losartan group (20.5+/-5.0%) than in enalapril (12.4+/-3.2%) and the losartan (9.1+/-2.1%) groups. Normalization of LVMI was obtained in 10 out of the 16 patients who received enalapril+ losartan, in 6 out of the 15 patients who received only enalapril and in 4 out of the 15 patients treated with losartan. CONCLUSION: The combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist (AT1 receptor antagonist) in patients produced an additional effect on the reduction of left ventricular hypertrophy. This finding may depend on a more complete inhibition of the cardiac renin-angiotensin. SN - 0066-782X UR - https://www.unboundmedicine.com/medline/citation/10904284/Reduction_in_left_ventricular_hypertrophy_in_hypertensive_patients_treated_with_enalapril_losartan_or_the_combination_of_enalapril_and_losartan_ L2 - https://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0066-782X2000000200001&amp;lng=en&amp;nrm=iso&amp;tlng=en DB - PRIME DP - Unbound Medicine ER -